Prothena (NASDAQ:PRTA) Issues Earnings Results

Prothena (NASDAQ:PRTA) posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.08, MarketWatch Earnings reports. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Prothena had a negative return on equity of 33.45% and a negative net margin of 13,978.88%.

Prothena stock traded down $0.14 during midday trading on Friday, reaching $9.37. 1,931 shares of the stock traded hands, compared to its average volume of 309,075. Prothena has a 12-month low of $8.63 and a 12-month high of $15.91. The stock has a market capitalization of $377.12 million, a price-to-earnings ratio of -2.60 and a beta of 2.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 27.85 and a quick ratio of 27.85.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Thursday, May 16th. BidaskClub cut Prothena from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, ValuEngine upgraded Prothena from a “sell” rating to a “hold” rating in a report on Tuesday, April 23rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. Prothena has a consensus rating of “Hold” and a consensus price target of $12.39.

Institutional investors have recently made changes to their positions in the stock. Quantamental Technologies LLC boosted its stake in shares of Prothena by 142.9% in the first quarter. Quantamental Technologies LLC now owns 4,129 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,429 shares in the last quarter. SG Americas Securities LLC acquired a new position in Prothena during the first quarter worth $114,000. Ellington Management Group LLC acquired a new position in Prothena during the first quarter worth $129,000. BNP Paribas Arbitrage SA raised its holdings in Prothena by 309.5% during the first quarter. BNP Paribas Arbitrage SA now owns 11,061 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 8,360 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Prothena by 7.5% during the fourth quarter. Legal & General Group Plc now owns 14,611 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 1,024 shares during the last quarter. Institutional investors own 98.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://rocklandregister.com/2019/05/31/prothena-prta-releases-earnings-results-beats-estimates-by-0-08-eps.html.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: What is required to own or exchange cryptocurrency?

Earnings History for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.